Business people chatting with each other

A Pharmaversity® Event

The future of ADCs:
How to overcome challenges in development & manufacturing

A joint event by Simtra BioPharma Solutions and SCHOTT Pharma

More information

As Antibody Drug Conjugates (ADCs) continue to pave the way as a future standard in cancer therapy their complex nature introduces challenges at every stage – from early development and fill & finish operations to drug-container interactions.

 

Join us to uncover effective solutions for safely developing, filling and storing Antibody Drug Conjugates

  • Discuss best practices for overcoming ADC formulations and stability challenges with SCHOTT Pharma and Simtra scientists, as well as academics and industry colleagues.
  • Discover Simtra BioPharma Solutions laboratories and world-class dedicated oncology filling lines.
  • Discover the latest trends in development and manufacturing and learn from renowned scientific experts and industry leaders actively engaged in ADC projects.
  • Meet and network with research & development thought leaders in the ADC space.
  • From lyophilization to light protection, discover how SCHOTT Pharma’s Specialty Vials help safeguard efficacy and reliability.
  • Discuss why container choice is key to safely storing your ADC.
  • Tour one of the world‘s largest manufacturing sites for ADCs. 

Don’t miss this opportunity to gain valuable insights into overcoming ADC challenges across the entire drug product value chain.

 

Program at a glance

Keynote Presentation

  • Challenges in formulation of highly sensitive biologics
    Prof. Dr. Wolfgang Friess, Ludwig-Maximilians-Universität-Munich

Expert Insights from SCHOTT Pharma & Simtra BioPharma Solutions
Primary Packaging for ADCs: Adressing Critical Challenges

  • Part 1 – Lyophilization, fogging and light sensitivity
    Dr. Bernhard Hladik & Sarawut Künzl, SCHOTT Pharma
  • Part 2 - Lyophilization versus liquid formulation
    Dr. Bernhard Hladik & Sarawut Künzl, SCHOTT Pharma 
  • Process Development for a Freeze-Dried Antibody Drug Conjugate | Case Study
    Dr. Gregory A. Sacha, Simtra BioPharma Solutions 
  • Overcoming challenges of critical environmental factors in manufacturing by thorough formulation development  
    Johanna Weber, Dr. Gregory A. Sacha, Simtra BioPharma Solutions

Exclusive behind-the-scenes tour

Experience an exclusive tour of Simtra's state-of-the-art manufacturing lines and laboratories.

Simtra BioPharma Solutions has a long-standing history in manufacturing Antibody Drug Conjugates and has transferred over 60 programs into its Halle/Westfalen, Germany manufacturing facility including six commercial ADC programs.

The site offers clinical and commercial manufacturing services, with expertise in oncology and ADCs, operating under SafeBridge classification and equipped to handle Category 4 drugs. The facility is currently undergoing a $100 million expansion to offer clients syringe manufacturing capacity as well as liquid and lyophilized vial capacity. An additional $14 million investment to expand its clinical-scale conjugation and purification capabilities for ADCs is set to be operational by late 2025.

For more details, you can see the announcement here.

As part of the ADC symposium you will get an exclusive tour of Simtra's state-of-the-art manufacturing lines and laboratories.

Man in the laboratory with sterile clothing
This event has already taken place, and registration is now closed.

Exciting plans are already in motion for the next major Pharmaversity® events! As soon as details are confirmed or new events are scheduled, you’ll find all the key information here:

Pharmaversity® Events